
Evozyne is a biotechnology company that creates novel protein systems aimed at solving longstanding challenges in therapeutic development. By leveraging advanced protein design and generative AI, Evozyne enhances protein performance to enable commercial-scale solutions, contributing to a healthier world. The company is well-funded and collaborates with top-tier investors and scientific advisors, positioning itself strongly in the biotech market focused on innovative therapeutic solutions.

Evozyne is a biotechnology company that creates novel protein systems aimed at solving longstanding challenges in therapeutic development. By leveraging advanced protein design and generative AI, Evozyne enhances protein performance to enable commercial-scale solutions, contributing to a healthier world. The company is well-funded and collaborates with top-tier investors and scientific advisors, positioning itself strongly in the biotech market focused on innovative therapeutic solutions.
Headquarters: Chicago, Illinois
Founded: 2020
Core tech: Generative AI (EvoGen) + high-throughput experimental biology (EvoLab)
Focus: De novo therapeutic protein design for immune-mediated diseases
Reported funding: Approximately $144.4M (across 3 rounds); Series B on 2023-09-27
Therapeutic protein design for immune-mediated and IgG-mediated diseases, including indications like inflammatory bowel disease.
2020
Biotechnology
Reported as most recent round; Crunchbase lists total of three rounds aggregating ~$144.4M.
“Backed by institutional investors including Fidelity, OrbiMed, Valor Equity Partners, Paragon Biosciences”
| Company |
|---|